Durham biopharma sells rights to smallpox countermeasure for up to $337M
Chimerix has agreed to sell its smallpox countermeasure to Emergent BioSolutions in a deal worth as much as $337 million.
Copy and paste this URL into your WordPress site to embed
Copy and paste this code into your site to embed
